In addition to a packed conference agenda and tours of the Pegasus Park healthcare and life science innovation hub in Dallas, ...

Throwing more money at SDoH programs isn’t going to magically fix them. Instead, plans should be focusing on building out ...

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...

Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration.

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular ...

As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational ...

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The ...

A new report on third quarter M&A activity in the healthcare sector found that this quarter’s hospital and health system ...

AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity.

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved ...

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...

Rick Abramson, a radiologist by training and the director of FDA's Digital Health Center of Excellence said, "We ended up ...